Immunosens Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 18

Immunosens General Information

Description

Developer of electrochemical measurement devices designed to evaluate biomarkers such as genes, proteins, and cell signals using electrode reactions. The company's devices use disposable, printable electrodes in their sensors, enabling healthcare professionals to perform accurate analyses and measurements for diagnosis and food safety inspection tests.

Contact Information

Website
immunosens.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6-1 Kishibe Shinmachi, Suita
  • National Cerebral and Cardiovascular Center, Open Innovation Lab 30602
  • Suita, Osaka 564-8565
  • Japan
+81
Primary Industry
Diagnostic Equipment
Vertical(s)
Nanotechnology, Manufacturing, Digital Health, HealthTech, Life Sciences
Corporate Office
  • 6-1 Kishibe Shinmachi, Suita
  • National Cerebral and Cardiovascular Center, Open Innovation Lab 30602
  • Suita, Osaka 564-8565
  • Japan
+81

Immunosens Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunosens Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 25-Aug-2026 Completed Generating Revenue
8. Product Crowdfunding 31-Aug-2025 Completed Generating Revenue
7. Accelerator/Incubator 29-Oct-2024 Completed Generating Revenue
6. Later Stage VC (Series B2) 02-Feb-2023 Completed Generating Revenue
5. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
4. Early Stage VC (Series B) 30-Jul-2021 Completed Generating Revenue
3. Early Stage VC (Series A) 02-Dec-2019 Completed Generating Revenue
2. Seed Round 24-Apr-2018 $561K $561K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Immunosens’s complete valuation and funding history, request access »

Immunosens Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B2
B Shares
A Shares 4,334 $230.6 $230.6 1x $230.6 13.97%
A1 Shares 4,000 $115.3 $115.3 1x $115.3 12.89%
To view Immunosens’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Immunosens Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Immunosens Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7820868-B1 Method for measuring test substance using electrochemical method Active 31-Jul-2025
JP-2026175868-A Method for measuring a test substance using electrochemical techniques Active 22-Apr-2025
JP-7748767-B1 Method for measuring test substance using electrochemical method Active 22-Apr-2025
WO-2026225492-A1 Method for measuring test substance using electrochemical technique Pending 22-Apr-2025
JP-2026008093-A Electrochemical immunosensor Active 04-Jul-2024
To view Immunosens’s complete patent history, request access »

Immunosens Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunosens Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
PAI -R Co., Ltd. Corporation Minority
J-StarX Accelerator/Incubator
Bussan Animal Health Corporation Minority
Global Brain Venture Capital Minority
Kirin Health Innovation Fund Corporate Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

Ready to get started?

Request a free trial

Immunosens FAQs

  • When was Immunosens founded?

    Immunosens was founded in 2018.

  • Where is Immunosens headquartered?

    Immunosens is headquartered in Suita, Japan.

  • What is the size of Immunosens?

    Immunosens has 20 total employees.

  • What industry is Immunosens in?

    Immunosens’s primary industry is Diagnostic Equipment.

  • Is Immunosens a private or public company?

    Immunosens is a Private company.

  • What is Immunosens’s current revenue?

    The current revenue for Immunosens is .

  • How much funding has Immunosens raised over time?

    Immunosens has raised $7.09M.

  • Who are Immunosens’s investors?

    PAI -R Co., Ltd., J-StarX, Bussan Animal Health, Global Brain, and Kirin Health Innovation Fund are 5 of 18 investors who have invested in Immunosens.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process